Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
In the realm of pharmaceutical research and development, understanding the precise chemical mechanisms of action for drug components is fundamental. N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-2-propenamide, identified by its CAS number 130929-57-6, is a prime example of a molecule whose chemical structure dictates its vital role as a catechol-O-methyltransferase (COMT) inhibitor.
The Role of COMT in Neurotransmission
Catechol-O-methyltransferase (COMT) is an enzyme found in various tissues, including the brain and peripheral organs. It plays a significant role in the metabolism of catecholamines, such as dopamine, norepinephrine, and epinephrine, by methylating their hydroxyl groups. In the context of Parkinson's disease treatment, COMT is particularly important because it metabolizes levodopa (L-DOPA), the precursor to dopamine. By breaking down levodopa in the periphery, COMT reduces the amount of levodopa that can cross the blood-brain barrier and exert its therapeutic effects.
CAS 130929-57-6: A Targeted Chemical Intervention
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-2-propenamide is designed to selectively inhibit COMT. Its chemical structure, particularly the presence of the nitrocatechol moiety, allows it to bind to the active site of the COMT enzyme. This binding effectively blocks the enzyme's catalytic activity, preventing it from methylating levodopa. The chemical design ensures that the inhibition is primarily peripheral, minimizing central nervous system side effects while maximizing levodopa's availability in the brain.
Drug Design Implications
The efficacy of N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-2-propenamide as a COMT inhibitor stems from its:
For researchers and formulators, procuring this intermediate from a reliable manufacturer is crucial to ensure the chemical integrity and effectiveness of the final drug product. Understanding the chemistry allows for better formulation strategies and therapeutic outcomes.
Conclusion
The chemical ingenuity behind N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-2-propenamide (CAS 130929-57-6) has made it a cornerstone in managing Parkinson's disease. Its targeted COMT inhibition exemplifies how precise chemical design can lead to significant therapeutic advancements. We offer this high-quality intermediate to support your drug design and development efforts.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
